Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume

Oculis Holding AG (NASDAQ:OCS) saw unusually-high trading volume on Tuesday . Approximately 52,187 shares changed hands during trading, an increase of 11% from the previous session’s volume of 47,215 shares.The stock last traded at $13.25 and had previously closed at $12.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th. Robert W. Baird decreased their price target on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a research note on Tuesday, March 19th. Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Oculis in a report on Tuesday, March 19th. Finally, HC Wainwright reduced their price objective on shares of Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, April 24th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Oculis currently has a consensus rating of “Buy” and a consensus target price of $29.14.

Oculis Trading Down 1.7 %

The stock’s 50-day moving average is $11.87 and its 200 day moving average is $11.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.29 and a quick ratio of 5.29.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.28 million. On average, research analysts forecast that Oculis Holding AG will post -1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

A number of institutional investors have recently modified their holdings of the business. Wolverine Asset Management LLC acquired a new stake in Oculis during the 3rd quarter worth $77,000. Compagnie Lombard Odier SCmA increased its stake in Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares during the period. abrdn plc purchased a new stake in shares of Oculis in the fourth quarter valued at about $15,980,000. Finally, Searle & CO. acquired a new stake in shares of Oculis during the fourth quarter worth about $112,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.